ロード中...
EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3
Programmed cell death (PD)-1/PD-1 ligand-1 (PD-L1)-targeted therapy has emerged as a promising therapeutic strategy for lung cancer. However, whether EML4-ALK regulates PD-L1 expression in lung cancer remains unknown. A total of 532 pulmonary adenocarcinomas (pADCs), including 58 ALK-translocated tu...
保存先:
| 出版年: | Oncoimmunology |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Taylor & Francis
2015
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4839370/ https://ncbi.nlm.nih.gov/pubmed/27141364 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1108514 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|